Results 171 to 180 of about 202,264 (382)

The comparison of calcium ion release and pH changes from modified MTA and bioceramics in regeneration

, 2017
Rendra Irawan, Anggraini Margono, NILAKESUMA DJAUHARI   +2 more
openalex   +1 more source

Az MTA Regionális Tudományos Bizottság újjáalakuló és tisztújító ülése

Tér és Társadalom, 1999
Regionális Tudományos Bizottság MTA
doaj   +1 more source

A mohácsi csata egy új képe – az MTA BTK Történettudományi Intézet egy új tanulmánykötete kapcsán

, 2019
Gábor Farkas Farkas
openalex   +2 more sources

Expanding the Genetic and Phenotypic Spectrum of DYT‐VPS16: The Importance of Splice‐Site Variants

Movement Disorders, EarlyView.
Abstract Background DYT‐VPS16, an early‐onset isolated dystonia caused by variants in the VPS16 gene, has been reported in fewer than 70 patients. Methods We explored the clinical and genotypic spectrum of DYT‐VPS16 by investigating early‐onset dystonia patients with VPS16 variants discovered in our large Biodatabank and through gene‐matching ...
Ana Westenberger, Edgard Verdura, Mandy Radefeldt, Leslie E. Sanderson, Kornelia Tripolszki, Anna Marcé‐Grau, Ana Cazurro‐Gutiérrez, Anita Nikoncuk, Rebecca Herzog, Ruslan Al‐Ali, Mariana Ferreira, Ligia S. Almeida, Tainá Regina Damaceno Silveira, Suliman Khan, Raphael Doyle Maia, Péter Klivényi, András Salamon, Volkan Baltaci, Asli Subasioglu, Jeanette Prada‐Arismendy, Goran Čuturilo, Sebastian Loens, Vera Tadic, Isabelle Maystadt, Deniz Karadurmus, Barbara Leube, Jonathan De Winter, Alice Monticelli, Liesbeth De Waele, Jonathan Baets, Mateja Vinkšel, Aleš Maver, Lorena Tschopp, Gabriela Ziegler, Ana Sanguinetti, Katja Lohmann, Tahsin Stefan Barakat, Peter Bauer, Belén Perez‐Dueñas, Aida M. Bertoli‐Avella   +39 more
wiley   +1 more source

Feasibility of Simon Two‐Stage Futility Trials in People with Early, Symptomatically Treated Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Disease‐modifying treatments are a critical unmet need in Parkinson's disease (PD). Phase 2 futility trials using the Simon two‐stage design offer an efficient strategy to evaluate candidate treatments in an early PD population. Objective The aim was to assess the feasibility of Simon two‐stage futility trials in early, levodopa ...
Marcus W. Koch, Lorraine V. Kalia, Justyna Sarna, Camila Aquino, Daryl Wile, Tiago A. Mestre, Michael G. Schlossmacher, Miguel D'Haeseleer, Jop Mostert, Eva M.M. Strijbis, Bernard Uitdehaag, Tarrant McPherson, Gary Cutter   +12 more
wiley   +1 more source

Effect of Graphene Incorporation on the Initial Setting Time of MTA and Biodentine: An In Vitro Pilot Study

Journal of Pharmacy and Bioallied Sciences
Introduction: Mineral Trioxide Aggregate (MTA) and Biodentine are two biocompatible materials that are commonly utilized in endodontics because they can seal and are bioactive. However, the long setup time of MTA is a problem in the clinic. Materials and
Hrishikesh Saoji, Dinesh Rao
doaj   +1 more source

MTA-Reformgesetz [PDF]

RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, 2020
openaire   +1 more source

Abstract PR006: Initial results from first-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in biomarker-selected solid tumors

, 2023
Jordi Rodón, Noboru Yamamoto, Toshihiko Doi, François Ghiringhelli, Maria-Elisabeth Goebeler, Yutaka Fujuwara, Miguel A. Villalona‐Calero, Nicolas Penel, Amita Patnaik, Jean‐Pascal Machiels, Alfredo Addeo, James L. Abbruzzese, Sophie Postel‐Vinay, Sylvie Rottey, Chunxu Liu, Chen-Hua Chuang, William Kormany, Paul E. Hughes, Kiana Keyvanjah, Bert H. O’Neil   +19 more
openalex   +2 more sources

Clinical study of Mineral Trioxide Aggregate in primary molars. Comparison between Grey and White MTA—A long term follow-up (84 months)

, 2010
Cristina Cardoso Silva, Elena Barbería, M. Romero Maroto, Franklin García‐Godoy   +3 more
openalex   +2 more sources

Transforming Care Across Countries: Lessons from the Integrated Care Networks for Parkinson's Disease Study (iCARE‐PD)

Movement Disorders, EarlyView.
Abstract Background The optimal design for care delivery in Parkinson's disease (PD) that addresses changing needs of the lived experience is unclear. There is a critical need for care models to be implemented and transferable across diverse healthcare systems with agility.
Deepa Dash, Margherita Fabbri, Joseph Saade, Marlena van Munster, David Pedrosa, Evzen Růžička, Ota Gal, Joaquim J. Ferreira, Álvaro Sánchez‐Ferro, Timothy Lynch, Carsten Eggers, Aashiyan Singh, David Grimes, Monica Taljaard, Oliver Rascol, Tiago A. Mestre, the iCARE‐PD consortium, Darlene Gilderson, Jennifer Conway, Beate Weber‐Schicker, John Inocentes, Petra Nesvacilova, Tatiana Trouchko, Mariana Nunes, Tiago Reis, Franziska Thieken, Stefanie Spriewald, Hana Brozova, Petr Holly, Christine Brefel‐Courbon, Fabienne Ory, Natalia del Campo, Estelle Harroch, Clémence Leung, Raquel Bouça   +34 more
wiley   +1 more source